Compare Amgen, Inc. (AMGN) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Fiverr International Ltd — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Fiverr International Ltd trades at $10.97 (market cap $396.90M). The key difference: Amgen, Inc. is far larger — about 494.1× Fiverr International Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| AMGN | FVRR | |
|---|---|---|
Market Cap | $196.12B | $396.90M |
Sector | Health | Industrials |
52-Week High | $388.16 | $27.25 |
52-Week Low | $271.18 | $9.62 |
Enterprise Value | $241.41B | $127.50M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Fiverr International (FVRR) trades at $11.04, up 1.1% on the day, with a bullish technical signal and strong valuation metrics including a P/E of 14.34 and P/S of 0.95. Revenue grew to $430.91M in 2025, with net income reaching $20.98M, though Q1 2026 EPS missed expectations. The company maintains a robust gross margin of 81.86% and has beaten earnings estimates in two of the last three quarters, with Q2 2026 results due July 29, 2026.
The outlook is mixed: low valuations and improving profitability support upside, but declining active buyers and a pending legal investigation pose risks. Analyst consensus is cautious with 41% buy ratings. Near-term performance hinges on Q2 earnings demonstrating growth stabilization amid competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
